| 32.88 2.18 (7.1%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 40.29 |
1-year : | 47.06 |
| Resists | First : | 34.5 |
Second : | 40.29 |
| Pivot price | 32.09 |
|||
| Supports | First : | 30.91 |
Second : | 28.7 |
| MAs | MA(5) : | 31.78 |
MA(20) : | 32.21 |
| MA(100) : | 37.61 |
MA(250) : | 0 | |
| MACD | MACD : | -0.8 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 44.8 |
D(3) : | 46.7 |
| RSI | RSI(14): 50.3 |
|||
| 52-week | High : | 48.45 | Low : | 17 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AAPG ] has closed below upper band by 30.1%. Bollinger Bands are 38.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 32.99 - 33.12 | 33.12 - 33.26 |
| Low: | 32.23 - 32.37 | 32.37 - 32.53 |
| Close: | 32.62 - 32.84 | 32.84 - 33.1 |
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor; APG-265, a MDM2 protein degrader; and UBX1967/1325, which are Bcl-2 inhibitors. In addition, it is also involved in medical research and development; clinical development; clinical trial operation; venture capital investment; rental services; and science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Fri, 05 Dec 2025
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down - Time to Sell? - MarketBeat
Thu, 04 Dec 2025
Ascentage Pharma Announces Global Registrational Phase III - GlobeNewswire
Mon, 01 Dec 2025
Ascentage Pharma to Highlight Key Data from ASH 2025 in Upcoming Webcast - TipRanks
Mon, 01 Dec 2025
Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025 - Yahoo Finance
Fri, 28 Nov 2025
AAPG - Ascentage Pharma Group International Latest Stock News & Market Updates - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 93 (M) |
| Shares Float | 264 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 3 (K) |
| Shares Short P.Month | 3 (K) |
| EPS | -2.05 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.94 |
| Profit Margin | -296.8 % |
| Operating Margin | -237.1 % |
| Return on Assets (ttm) | -22.8 % |
| Return on Equity (ttm) | -159.7 % |
| Qtrly Rev. Growth | -71.6 % |
| Gross Profit (p.s.) | 3.81 |
| Sales Per Share | 4.2 |
| EBITDA (p.s.) | -11.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -189 (M) |
| Levered Free Cash Flow | 36 (M) |
| PE Ratio | -16.04 |
| PEG Ratio | 0 |
| Price to Book value | 16.94 |
| Price to Sales | 7.82 |
| Price to Cash Flow | -16.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|